Literature DB >> 23010104

For whom the bell tolls: distress signals from long-lived osteocytes and the pathogenesis of metabolic bone diseases.

Stavros C Manolagas1, A Michael Parfitt.   

Abstract

Osteocytes are long-lived and far more numerous than the short-lived osteoblasts and osteoclasts. Immured within the lacunar-canalicular system and mineralized matrix, osteocytes are ideally located throughout the bone to detect the need for, and accordingly choreograph, the bone regeneration process by independently controlling rate limiting steps of bone resorption and formation. Consistent with this role, emerging evidence indicates that signals arising from apoptotic and old/or dysfunctional osteocytes are seminal culprits in the pathogenesis of involutional, post-menopausal, steroid-, and immobilization-induced osteoporosis. Osteocyte-originated signals may also contribute to the increased bone fragility associated with bone matrix disorders like osteogenesis imperfecta, and perhaps the rapid reversal of bone turnover above baseline following discontinuation of anti-resorptive treatments, like denosumab. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23010104      PMCID: PMC3574964          DOI: 10.1016/j.bone.2012.09.017

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  82 in total

1.  Endocrinology: bone adaptation requires oestrogen receptor-alpha.

Authors:  Karla Lee; Helen Jessop; Rosemary Suswillo; Gul Zaman; Lance Lanyon
Journal:  Nature       Date:  2003-07-24       Impact factor: 49.962

Review 2.  Is the paradigm shifting?

Authors:  Robert P Heaney
Journal:  Bone       Date:  2003-10       Impact factor: 4.398

3.  Strain-derived canalicular fluid flow regulates osteoclast activity in a remodelling osteon--a proposal.

Authors:  Elisabeth H Burger; Jenneke Klein-Nulend; Theo H Smit
Journal:  J Biomech       Date:  2003-10       Impact factor: 2.712

Review 4.  Sex steroids and bone.

Authors:  S C Manolagas; S Kousteni; R L Jilka
Journal:  Recent Prog Horm Res       Date:  2002

5.  Relationships between osteocyte density and bone formation rate in human cancellous bone.

Authors:  S Qiu; D S Rao; S Palnitkar; A M Parfitt
Journal:  Bone       Date:  2002-12       Impact factor: 4.398

6.  Reduced iliac cancellous osteocyte density in patients with osteoporotic vertebral fracture.

Authors:  Shijing Qiu; D Sudhaker Rao; Saroj Palnitkar; A Michael Parfitt
Journal:  J Bone Miner Res       Date:  2003-09       Impact factor: 6.741

Review 7.  Sex steroids and the construction and conservation of the adult skeleton.

Authors:  B Lawrence Riggs; Sundeep Khosla; L Joseph Melton
Journal:  Endocr Rev       Date:  2002-06       Impact factor: 19.871

8.  Reversal of bone loss in mice by nongenotropic signaling of sex steroids.

Authors:  S Kousteni; J R Chen; T Bellido; L Han; A A Ali; C A O'Brien; L Plotkin; Q Fu; A T Mancino; Y Wen; A M Vertino; C C Powers; S A Stewart; R Ebert; A M Parfitt; R S Weinstein; R L Jilka; S C Manolagas
Journal:  Science       Date:  2002-10-25       Impact factor: 47.728

9.  Age and distance from the surface but not menopause reduce osteocyte density in human cancellous bone.

Authors:  S Qiu; D S Rao; S Palnitkar; A M Parfitt
Journal:  Bone       Date:  2002-08       Impact factor: 4.398

10.  Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist.

Authors:  Rutger L van Bezooijen; Bernard A J Roelen; Annemieke Visser; Lianne van der Wee-Pals; Edwin de Wilt; Marcel Karperien; Herman Hamersma; Socrates E Papapoulos; Peter ten Dijke; Clemens W G M Löwik
Journal:  J Exp Med       Date:  2004-03-15       Impact factor: 14.307

View more
  23 in total

1.  A new approach to iliac bone histomorphometry: implications for biomechanics and cell biology.

Authors:  A Michael Parfitt
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

2.  The Quest for Osteoporosis Mechanisms and Rational Therapies: How Far We've Come, How Much Further We Need to Go.

Authors:  Stavros C Manolagas
Journal:  J Bone Miner Res       Date:  2018-02-22       Impact factor: 6.741

Review 3.  A look behind the scenes: the risk and pathogenesis of primary osteoporosis.

Authors:  Gretl Hendrickx; Eveline Boudin; Wim Van Hul
Journal:  Nat Rev Rheumatol       Date:  2015-04-21       Impact factor: 20.543

Review 4.  Functional impairment of bone formation in the pathogenesis of osteoporosis: the bone marrow regenerative competence.

Authors:  Joseph P Bidwell; Marta B Alvarez; Mark Hood; Paul Childress
Journal:  Curr Osteoporos Rep       Date:  2013-06       Impact factor: 5.096

Review 5.  Molecular and cellular basis of bone resorption.

Authors:  Reinhard Gruber
Journal:  Wien Med Wochenschr       Date:  2014-09-16

6.  β-aminoisobutyric Acid, l-BAIBA, Is a Muscle-Derived Osteocyte Survival Factor.

Authors:  Yukiko Kitase; Julian A Vallejo; William Gutheil; Harika Vemula; Katharina Jähn; Jianxun Yi; Jingsong Zhou; Marco Brotto; Lynda F Bonewald
Journal:  Cell Rep       Date:  2018-02-06       Impact factor: 9.423

7.  Inflammation-induced lymphatic architecture and bone turnover changes are ameliorated by irisin treatment in chronic inflammatory bowel disease.

Authors:  S Anand Narayanan; Corinne E Metzger; Susan A Bloomfield; David C Zawieja
Journal:  FASEB J       Date:  2018-03-29       Impact factor: 5.191

Review 8.  Wnt signaling and osteoporosis.

Authors:  Stavros C Manolagas
Journal:  Maturitas       Date:  2014-04-24       Impact factor: 4.342

Review 9.  The role of estrogen and androgen receptors in bone health and disease.

Authors:  Stavros C Manolagas; Charles A O'Brien; Maria Almeida
Journal:  Nat Rev Endocrinol       Date:  2013-09-17       Impact factor: 43.330

10.  Dysapoptosis of osteoblasts and osteocytes increases cancellous bone formation but exaggerates cortical porosity with age.

Authors:  Robert L Jilka; Charles A O'Brien; Paula K Roberson; Lynda F Bonewald; Robert S Weinstein; Stavros C Manolagas
Journal:  J Bone Miner Res       Date:  2014-01       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.